Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04840394 is registered in ClinicalTrials.gov with Eikon Therapeutics as lead sponsor.

NCT NCT04840394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04840394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Lead sponsor
Eikon Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
June 22, 2021
Completion date
September 30, 2024
Enrollment
1 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

tumor, solid